Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

Personalis will present six clinical abstracts at the ASCO 2026 Annual Meeting, highlighting the broad utility of its NeXT Personal ctDNA test across six solid tumor types. A key highlight is an oral podium presentation from the TRACERx consortium, demonstrating that NeXT Personal’s single-digit parts-per-million sensitivity identifies high-relapse-risk patients in early-stage non-small cell lung cancer.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.